ScAAV9 regulatory update

FDA granted breakthrough therapy designation to AVXS-101 from AveXis to treat spinal muscular atrophy (SMA) type 1. The therapy is in Phase I testing and uses RegenxBio’s NAV rAAV9 vector technology t...